drugset / Trial / NCT00665457
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase II clinical trial is studying biomarkers and side effects in women receiving chemotherapy and celecoxib for stage II or stage III breast cancer that can be removed by surgery.
Timeline
- Start
- 2004-04-15
- Primary completion
- 2009-07-31
- Completion
- 2009-07-31
Outcome
Outcome not reported
Stopped (Enrollment): “study drug was removed from the market and low enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Celecoxib | Other / unclassified | — | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |